Dr. Mitchell

Edith P. Mitchell, MD, FACP

Contact Dr. Mitchell

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874
(215) 503-9506 fax

Most Recent Peer-reviewed Publications

  1. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
  2. American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce
  3. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer
  4. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
  5. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: A phase II Eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205)
  6. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
  7. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms
  8. African American Patients’ Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment
  9. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
  10. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
  11. Moonshot Toward a Cure for Cancer
  12. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism
  13. Positive association of fibroadenomatoid change with HER2-negative invasive breast cancer: A co-occurrence study
  14. 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: A randomized Phase IIb study
  15. Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer
  16. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
  17. Determinants of pain severity changes in ambulatory patients with cancer: An analysis from eastern cooperative oncology group trial E2Z02
  18. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA
  19. Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass
  20. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer